Elevation Oncology

Member Type: Emerging Biotech/Pharmaceutical Companies

Elevation Oncology is founded on the belief that all patients with cancer deserve to know what is driving the growth of their disease and have access to therapeutics that can stop it. Elevation is making genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. The company's lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today

Download a Member List